ARBELE biopharmaceutical company based in Hong Kong Science & Technology Park since May 2016, focuses on acceleration and expansion of immunotherapy technology and product development to treat cancers prevalent in Greater China, Asia-Pacific and the USA. Two R&D sites (HK & Seattle WA) have been established to leverage local expertise from Research & Innovation to Translational & Clinical Development. The company has established a stellar collaboration network with leading academic institutes, biotechs, and medical centers to progress the clinical stage of drug candidates. The most advanced product candidate is planned for clinical development in 2017, based on our proprietary cancer target CDH17 (liver-intestine cadherin) for liver tumor (also indications for stomach, colon, esophageal and pancreatic). Capitalizing big-data and next-gen sequencing, the company is developing companion diagnostics and molecular imaging to detect cancers and predict clinical outcomes
Chimeric Antigen Receptor (CAR) technology directs T and NK (natural killer) cells to recognize cancer cells based on expression of specific cell surface proteins.
The use of bispecific antibodies, targeting two tumor antigens for cancer treatment. This approach evolves to BiTE therapeutics, a bi-specific mAb that forms a link between tumor and T cells, causing cancer cell death.
Using high-throughput and cutting-edge DNA sequencing technology, we can identify the oncogenes and mutations unique in patient's samples - tumor and liquid biopsies for early diagnosis and precision treatments.
Arbele is positioned to be a leader in cancer immunotherapies for solid tumors. A central player in cancer immunotherapy is a type of white blood cell known as the T cell. In healthy individuals, T cells identify and kill infected or abnormal cells like tumors. However, cancer cells carrying the ability (especially in solid tumors) to evade immune surveillance is a key factor in their growth, spread, and persistence. We leverage two technologies - Chimeric Antigen Receptor (CAR) and Bi-specific Monoclonal Antibodies (BiMAbs) - to activate the patient's T cells so that they attack cancer cells.READ MORE